A new class of compounds that incorporated the structural motif of the 1-(3',4',5'-trimethoxtbenzoyl)-3-arylamino-5-amino-1,2,4-triazole molecular skeleton was synthesized and evaluated for their antiproliferative activity in vitro, interactions with tubulin, and cell cycle effects. The most active agent, 3c, was evaluated for antitumor activity in vivo. Structure-activity relationships were elucidated with various substituents on the phenyl ring of the anilino moiety at the C-3 position of the 1,2,4-triazole ring. The best results for inhibition of cancer cell growth were obtained with the p-Me, m,p-diMe, and p-Et phenyl derivatives 3c, 3e, and 3f, respectively, and overall, these compounds were more or less as active as CA-4. Their vascular disrupting activity was evaluated in HUVEC cells, with compound 3c showing activity comparable with that of CA-4. Compound 3c almost eliminated the growth of syngeneic hepatocellular carcinoma in Balb/c mice, suggesting that 3c could be a new antimitotic agent with clinical potential.
A new class of pan> class="Chemical">compounds that incorporated the structural motif of the 1-(3',4',5'-trimethoxtbenzoyl)-3-arylamino-5-amino-1,2,4-triazole molecular skeleton was synthesized and evaluated for their antiproliferative activity in vitro, interactions with tubulin, and cell cycle effects. The most active agent, 3c, was evaluated for antitumor activity in vivo. Structure-activity relationships were elucidated with various substituents on the phenyl ring of the anilino moiety at the C-3 position of the 1,2,4-triazole ring. The best results for inhibition of cancercell growth were obtained with the p-Me, m,p-diMe, and p-Et phenyl derivatives 3c, 3e, and 3f, respectively, and overall, these compounds were more or less as active as CA-4. Their vascular disrupting activity was evaluated in HUVECcells, with compound 3c showing activity comparable with that of CA-4. Compound 3c almost eliminated the growth of syngeneic hepatocellular carcinoma in Balb/cmice, suggesting that 3ccould be a new antimitotic agent with clinical potential.
Authors: M Zweifel; G C Jayson; N S Reed; R Osborne; B Hassan; J Ledermann; G Shreeves; L Poupard; S-P Lu; J Balkissoon; D J Chaplin; G J S Rustin Journal: Ann Oncol Date: 2011-01-27 Impact factor: 32.976
Authors: Romeo Romagnoli; Pier Giovanni Baraldi; Maria Kimatrai Salvador; Delia Preti; Mojgan Aghazadeh Tabrizi; Andrea Brancale; Xian-Hua Fu; Jun Li; Su-Zhan Zhang; Ernest Hamel; Roberta Bortolozzi; Giuseppe Basso; Giampietro Viola Journal: J Med Chem Date: 2011-12-21 Impact factor: 7.446
Authors: Jos H M Lange; Herman H van Stuivenberg; Hein K A C Coolen; Tiny J P Adolfs; Andrew C McCreary; Hiskias G Keizer; Henri C Wals; Willem Veerman; Alice J M Borst; Wouter de Looff; Peter C Verveer; Chris G Kruse Journal: J Med Chem Date: 2005-03-24 Impact factor: 7.446
Authors: Dietmar W Siemann; Michael C Bibby; Graham G Dark; Adam P Dicker; Ferry A L M Eskens; Michael R Horsman; Dieter Marmé; Patricia M Lorusso Journal: Clin Cancer Res Date: 2005-01-15 Impact factor: 12.531
Authors: G J Rustin; G Shreeves; P D Nathan; A Gaya; T S Ganesan; D Wang; J Boxall; L Poupard; D J Chaplin; M R L Stratford; J Balkissoon; M Zweifel Journal: Br J Cancer Date: 2010-04-13 Impact factor: 7.640
Authors: Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman Journal: Nat Rev Drug Discov Date: 2006-03 Impact factor: 84.694